(WVE)


Exchange


Currency in (Disclaimer)
Volume:
Day's Range:

WVE Insider Transactions

Transaction Date
(SEC Report )
Reporting Name Relationship Shrs. Owned Type Acq./Disp. Shrs. Transacted Price() Amount()
2023-02-17 Vargeese Chandra officer: Chief Technology Officer, Head of Platform Discovery Sciences 295,400 A-Award A 295,400 4.75 1,403,150.00
2023-02-17 BOLNO PAUL director, officer: President and CEO 771,000 A-Award A 771,000 4.75 3,662,250.00
2023-02-17 Francis Chris officer: SVP, Corporate Development, Head of Emerging Areas 244,700 A-Award A 244,700 4.75 1,162,325.00
2023-02-17 Moran Kyle officer: Chief Financial Officer 272,700 A-Award A 272,700 4.75 1,295,325.00
2023-02-16 Vargeese Chandra officer: Chief Technology Officer, Head of Platform Discovery Sciences 106,624 S-Sale D 10,249 4.03 41,303.47
2023-02-16 BOLNO PAUL director, officer: President and CEO 407,425 S-Sale D 29,400 4.04 118,776.00
2023-02-16 Francis Chris officer: SVP, Corporate Development, Head of Emerging Areas 79,714 S-Sale D 10,258 4.03 41,339.74
2023-02-16 Moran Kyle officer: Chief Financial Officer 79,751 S-Sale D 9,729 4.04 39,305.16
2022-10-27 Verdine Gregory L. director 163,467 A-Award A 163,467 4.37 714,350.79
2022-08-15 Tan Aik Na director 21,000 A-Award A 21,000 3.50 73,500.00
2022-08-15 CORRIGAN MARK director 21,000 A-Award A 21,000 3.50 73,500.00
2022-08-15 TAKANASHI KEN director, 10 percent owner 21,000 A-Award A 21,000 3.50 73,500.00
2022-08-15 Wagner Heidi L director 21,000 A-Award A 21,000 3.50 73,500.00
2022-08-15 Verdine Gregory L. director 21,000 A-Award A 21,000 3.50 73,500.00
2022-08-15 HENRY CHRISTIAN O director 21,000 A-Award A 21,000 3.50 73,500.00
2022-08-15 Rawcliffe Adrian director 21,000 A-Award A 21,000 3.50 73,500.00
2022-08-15 RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner 21,000 A-Award A 21,000 3.50 73,500.00
2022-07-25 Moran Kyle officer: Chief Financial Officer 60,000 A-Award A 60,000 2.83 169,800.00
2022-07-25 Francis Chris officer: SVP, Corporate Development, Head of Emerging Areas 45,000 A-Award A 45,000 2.83 127,350.00
2022-07-25 BOLNO PAUL director, officer: President and CEO 180,000 A-Award A 180,000 2.83 509,400.00
2022-07-25 Panzara Michael A. officer: Chief Medical Officer, Head of Therapeutics Discovery and Development 60,000 A-Award A 60,000 2.83 169,800.00
2022-07-25 Vargeese Chandra officer: Chief Technology Officer, Head of Platform Discovery Sciences 60,000 A-Award A 60,000 2.83 169,800.00
2022-06-16 RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner 7,093,656 P-Purchase A 7,093,656 0.00 709.37
2022-06-16 RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner 17,202,009 P-Purchase A 9,480,052 2.15 20,382,111.80
2022-05-05 Vargeese Chandra officer: Chief Technology Officer, Head of Platform Discovery Sciences 111,095 S-Sale D 16,714 1.72 28,748.08
2022-05-05 Francis Chris officer: SVP, Corporate Development, Head of Emerging Areas 89,972 S-Sale D 10,867 1.72 18,691.24
2022-05-05 Moran Kyle officer: Chief Financial Officer 84,567 S-Sale D 5,021 1.72 8,636.12
2022-05-05 BOLNO PAUL director, officer: President and CEO 436,825 S-Sale D 33,501 1.72 57,621.72
2022-05-05 Panzara Michael A. officer: Chief Medical Officer, Head of Therapeutics Discovery and Development 109,103 S-Sale D 16,714 1.72 28,748.08
2022-05-04 Vargeese Chandra officer: Chief Technology Officer, Head of Platform Discovery Sciences 127,809 A-Award A 50,000 0.00 0.00
2022-05-04 Francis Chris officer: SVP, Corporate Development, Head of Emerging Areas 100,839 A-Award A 32,500 0.00 0.00
2022-05-04 Moran Kyle officer: Chief Financial Officer 89,588 A-Award A 15,000 0.00 0.00
2022-05-04 BOLNO PAUL director, officer: President and CEO 470,326 A-Award A 92,500 0.00 0.00
2022-05-04 Panzara Michael A. officer: Chief Medical Officer, Head of Therapeutics Discovery and Development 125,817 A-Award A 50,000 0.00 0.00
2022-02-16 Moran Kyle officer: Chief Financial Officer 74,588 S-Sale D 9,204 2.31 21,261.24
2022-02-16 Francis Chris officer: SVP, Corporate Development, Head of Emerging Areas 68,339 S-Sale D 10,123 2.31 23,384.13
2022-02-16 Vargeese Chandra officer: Chief Technology Officer 77,809 S-Sale D 10,603 2.32 24,598.96
2022-02-16 BOLNO PAUL director, officer: President and CEO 377,826 S-Sale D 33,150 2.32 76,908.00
2022-02-16 Panzara Michael A. officer: Chief Medical Officer, Head of Therapeutics Discovery and Development 75,817 S-Sale D 10,603 2.31 24,492.93
2022-01-01 Vargeese Chandra officer: Chief Technology Officer 200,000 A-Award A 200,000 3.14 628,000.00
2022-01-01 Francis Chris officer: SVP, Corporate Development, Head of Emerging Areas 150,000 A-Award A 150,000 3.14 471,000.00
2022-01-01 BOLNO PAUL director, officer: President and Chief Executive Officer 600,000 A-Award A 600,000 3.14 1,884,000.00
2022-01-01 Panzara Michael A. officer: Chief Medical Officer, Head of Therapeutics Discovery and Development 200,000 A-Award A 200,000 3.14 628,000.00
2022-01-01 Moran Kyle officer: Chief Financial Officer 175,000 A-Award A 175,000 3.14 549,500.00
2021-08-16 CORRIGAN MARK director 21,000 A-Award A 21,000 5.97 125,370.00
2021-08-16 Rawcliffe Adrian director 42,000 A-Award A 42,000 5.97 250,740.00
2021-08-16 Verdine Gregory L. director 42,000 A-Award A 42,000 5.97 250,740.00
2021-08-16 TAKANASHI KEN director, 10 percent owner 42,000 A-Award A 42,000 5.97 250,740.00
2021-08-16 HENRY CHRISTIAN O director 42,000 A-Award A 42,000 5.97 250,740.00
2021-08-16 Tan Aik Na director 21,000 A-Award A 21,000 5.97 125,370.00
2021-08-16 Wagner Heidi L director 21,000 A-Award A 21,000 5.97 125,370.00
2021-08-16 RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner 42,000 A-Award A 42,000 5.97 250,740.00
2021-04-01 RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner 7,573,613 J-Other A 768,431 5.61 4,310,897.91
2021-04-01 RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner 201,594 J-Other A 201,594 5.61 1,130,942.34
2021-03-24 Moran Kyle officer: Chief Financial Officer 80,792 M-Exempt A 10,930 2.48 27,106.40
2021-03-24 Moran Kyle officer: Chief Financial Officer 25,000 M-Exempt D 10,930 2.48 27,106.40
2021-02-16 Moran Kyle officer: Chief Financial Officer 69,862 S-Sale D 1,722 10.57 18,201.54
2021-02-16 Vargeese Chandra officer: Senior VP, Drug Discovery 85,412 S-Sale D 3,145 10.57 33,242.65
2021-02-16 Panzara Michael A. officer: Chief Medical Officer 86,420 S-Sale D 2,929 10.57 30,959.53
2021-02-16 BOLNO PAUL director, officer: President and CEO 410,976 S-Sale D 11,205 10.57 118,436.85
2021-02-16 Francis Chris officer: See Remarks 78,462 S-Sale D 2,698 10.57 28,517.86
2021-02-01 Moran Kyle officer: Chief Financial Officer 71,584 A-Award A 50,000 10.48 524,000.00
2021-02-01 Moran Kyle officer: Chief Financial Officer 50,000 A-Award A 50,000 10.48 524,000.00
2021-02-01 Vargeese Chandra officer: Senior VP, Drug Discovery 88,557 A-Award A 50,000 10.48 524,000.00
2021-02-01 Vargeese Chandra officer: Senior VP, Drug Discovery 50,000 A-Award A 50,000 10.48 524,000.00
2021-02-01 Panzara Michael A. officer: Chief Medical Officer 89,349 A-Award A 50,000 10.48 524,000.00
2021-02-01 Panzara Michael A. officer: Chief Medical Officer 50,000 A-Award A 50,000 10.48 524,000.00
2021-02-01 BOLNO PAUL director, officer: President and CEO 422,181 A-Award A 150,000 0.00 0.00
2021-02-01 BOLNO PAUL director, officer: President and CEO 200,000 A-Award A 200,000 10.48 2,096,000.00
2021-02-01 Francis Chris officer: See Remarks 81,160 A-Award A 50,000 10.48 524,000.00
2021-02-01 Francis Chris officer: See Remarks 50,000 A-Award A 50,000 10.48 524,000.00
2020-09-15 BOLNO PAUL director, officer: President and CEO 372,181 M-Exempt A 100,000 2.48 248,000.00
2020-09-15 BOLNO PAUL director, officer: President and CEO 272,181 S-Sale D 100,000 2.48 248,000.00
2020-09-15 BOLNO PAUL director, officer: President and CEO 97,778 M-Exempt D 100,000 2.48 248,000.00
2020-08-25 BOLNO PAUL director, officer: President and CEO 297,181 M-Exempt A 25,000 2.48 62,000.00
2020-08-25 BOLNO PAUL director, officer: President and CEO 272,181 S-Sale D 25,000 2.48 62,000.00
2020-08-25 BOLNO PAUL director, officer: President and CEO 197,778 M-Exempt D 25,000 2.48 62,000.00
2020-08-18 Rawcliffe Adrian director 10,500 A-Award A 10,500 9.13 95,865.00
2020-08-18 CORRIGAN MARK director 10,500 A-Award A 10,500 9.13 95,865.00
2020-08-18 Pott Amy director 10,500 A-Award A 10,500 9.13 95,865.00
2020-08-18 Kolchinsky Peter director, 10 percent owner 10,500 A-Award A 10,500 9.13 95,865.00
2020-08-18 Verdine Gregory L. director 10,500 A-Award A 10,500 9.13 95,865.00
2020-08-18 Tan Aik Na director 21,000 A-Award A 21,000 9.13 191,730.00
2020-08-18 HENRY CHRISTIAN O director 10,500 A-Award A 10,500 9.13 95,865.00
2020-08-18 Wagner Heidi L director 10,500 A-Award A 10,500 9.13 95,865.00
2020-08-18 TAKANASHI KEN director, 10 percent owner 10,500 A-Award A 10,500 9.13 95,865.00
2020-07-02 BOLNO PAUL director, officer: President and CEO 315,249 S-Sale D 4,509 10.82 48,787.38
2020-07-02 BOLNO PAUL director, officer: President and CEO 272,181 S-Sale D 43,068 10.26 441,877.68
2020-07-02 BOLNO PAUL director, officer: President and CEO 372,181 M-Exempt A 100,000 2.48 248,000.00
2020-07-02 BOLNO PAUL director, officer: President and CEO 368,102 S-Sale D 4,079 10.91 44,501.89
2020-07-02 BOLNO PAUL director, officer: President and CEO 222,778 M-Exempt D 100,000 2.48 248,000.00
2020-03-03 Vargeese Chandra officer: Senior VP, Drug Discovery 36,000 A-Award A 36,000 8.17 294,120.00
2020-03-03 BOLNO PAUL director, officer: President and CEO 63,000 A-Award A 63,000 8.17 514,710.00
2020-03-03 Gaiero David G officer: Interim CFO 18,000 A-Award A 18,000 8.17 147,060.00
2020-03-03 Panzara Michael A. officer: Chief Medical Officer 36,000 A-Award A 36,000 8.17 294,120.00
2020-03-03 Francis Chris officer: See Remarks 36,000 A-Award A 36,000 8.17 294,120.00
2020-02-18 BOLNO PAUL director, officer: President and CEO 319,758 S-Sale D 11,451 7.85 89,890.35
2020-02-18 Francis Chris officer: See Remarks 31,160 S-Sale D 2,708 7.85 21,257.80
2020-02-18 Panzara Michael A. officer: Chief Medical Officer 39,349 S-Sale D 2,981 7.85 23,400.85
2020-02-18 Vargeese Chandra officer: Senior VP, Drug Discovery 37,057 S-Sale D 3,188 7.85 25,025.80

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.